Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.31
- Piotroski Score 7.00
- Grade Sector Outperform
- Symbol (CSTL)
- Company Castle Biosciences, Inc.
- Price $28.84
- Changes Percentage (1.35%)
- Change $0.39
- Day Low $28.38
- Day High $29.71
- Year High $35.84
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $40.50
- High Stock Price Target $45.00
- Low Stock Price Target $36.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.13
- Trailing P/E Ratio -20.49
- Forward P/E Ratio -20.49
- P/E Growth -20.49
- Net Income $-57,466,000
Income Statement
Quarterly
Annual
Latest News of CSTL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Castle Biosciences, Inc.'s (NASDAQ:CSTL) Intrinsic Value Is Potentially 95% Above Its Share Price
Castle Biosciences' intrinsic value is 85% higher than its analyst price target. Using a Discounted Cash Flow model, the company's future cash flows are projected to be US$1....
By Yahoo! Finance | 1 month ago -
Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL)
Kristen Oelschlager, COO of Castle Biosciences Inc, sold 5,832 shares, now owning 134,841 shares. The company provides cancer diagnostic tests. Oelschlager has sold 24,407 shares in the past year....
By Yahoo! Finance | 2 months ago -
Investors in Castle Biosciences (NASDAQ:CSTL) have unfortunately lost 71% over the last three years
Despite Castle Biosciences Inc. (NASDAQ:CSTL) experiencing a 71% decline in the past three years, its revenue has grown by 42% annually. The company's profitability issues may be impacting its stock p...
By Yahoo! Finance | 3 months ago
